Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3431-3433

  Kroeger, Lisa A ^a   Hovde, Laurie B ^a   Mitropoulos, Isaac F ^a   Schafer, Jeremy ^a   Rotschafer, John C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; COLISTIMETHATE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL GROWTH; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; COLISTIN; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS;

EID: 35348937025     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01433-06     Document Type: Article

References (10)

1. Don Whitley Scientific Ltd. 2000. WASP 2 user manual. Don Whitley Scientific Ltd., Shipley, West Yorkshire, England.
2. Gales, A. C., R. N. Jones, K. R. Forward, J. Linares, H. S. Sader, and J. Verhoef. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin. Infect. Dis. 32:S104-S113.
3. Garnacho-Montero, J., C. Ortiz-Leyba, E. Fernández-Hinojosa, T. Aldabó-Pallás, A. Cayuela, J. A. Marquez-Vácaro, A. Garcia-Curiel, and F. J. Jiménez-Jiménez. 2005. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 31:649-655.
4. Gaynes, R., J. R. Edwards, and the National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
5. Karlowsky, J. A., D. C. Draghi, M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688.
6. Li, J., R. W. Milne, R. L. Nation, J. D. Turnidge, and K. Coulthard. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47:1364-1370.
7. NCCLS. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 5th ed. NCCLS document M7-A5. NCCLS, Wayne, PA.
8. Reed, M. D., R. C. Stern, M. A. O'Riordan, and J. L. Blumer. 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41:645-654.
9. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
10. Zabinski, R. A., K. Vance-Bryan, A. J. Krinke, K. J. Walker, J. A. Moody, and J. C. Rotschafer. 1993. Evaluation of activity of temafloxacin against Bacteroides fragalis by an in vitro pharmacodynamic system. Antimicrob. Agents Chemother. 37:2454-2458.